We could not find any results for:
Make sure your spelling is correct or try broadening your search.
NOX-E36 bietet vielversprechende Entwicklungsmöglichkeiten für Augenkrankheiten mit einem hohen Bedarf an gut verträglichen Therapien mit antifibrotischer Wirkung Die antifibrotische...
NOX-E36 presents promising opportunity for development in eye diseases with a high need for well-tolerated therapies with anti-fibrotic effect Anti-fibrotic mode of action of NOX-E36 was...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.035 | 28.4552845528 | 0.123 | 0.18 | 0.123 | 1029348 | 0.15615522 | DE |
4 | 0.0354 | 28.8743882545 | 0.1226 | 0.18 | 0.1174 | 449812 | 0.14752362 | DE |
12 | 0.0108 | 7.33695652174 | 0.1472 | 0.18 | 0.1128 | 446866 | 0.1464109 | DE |
26 | -0.0845 | -34.8453608247 | 0.2425 | 0.26 | 0.1128 | 365183 | 0.16006507 | DE |
52 | -0.213 | -57.4123989218 | 0.371 | 0.47 | 0.1128 | 600812 | 0.24915277 | DE |
156 | 0.1162 | 277.990430622 | 0.0418 | 5.98 | 0.0398 | 313196 | 0.36177489 | DE |
260 | 0.1162 | 277.990430622 | 0.0418 | 5.98 | 0.0398 | 313196 | 0.36177489 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions